March 3, 2020 / 7:49 AM / a month ago

BRIEF-Transgene And BioInvent To Present Data On BT-001

March 3 (Reuters) - TRANSGENE SA:

* TRANSGENE AND BIOINVENT TO PRESENT DATA ON BT-001, AN ONCOLYTIC VIRUS ENCODING FOR AN ANTI-CTLA4 ANTIBODY, AT UPCOMING CONGRESSES

* COMPREHENSIVE DATA PACKAGE SUPPORTS PENDING CLINICAL TRIAL APPLICATION FOR FIRST-IN-HUMAN STUDY OF BT-001

* ONCOLYTIC VIRUS DESIGN AND PRECLINICAL DATA TO BE PRESENTED AT ESMO TAT, IO SUMMIT EUROPE, KEYSTONE SYMPOSIUM AND AACR 2020

* WE ARE VERY MUCH LOOKING FORWARD TO INVESTIGATE BT-001 IN ITS FIRST-IN-HUMAN STUDY, WHICH IS PLANNED TO START BEFORE END OF 2020.

* FIRST-IN-HUMAN TRIAL IS EXPECTED TO START BEFORE END OF 2020 IN EUROPE AND USA. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below